Prognostic Value of Thermodilution-derived Coronary Flow Capacity in Patients with Deferred Revascularization.
To investigate the prognostic value of thermodilution-derived coronary flow capacity (T-CFC) in patients with stable coronary artery disease and deferred revascularization. We evaluated 308 lesions in 308 patients with deferred revascularization, stratifying the cohort according to T-CFC. Ischemic T-CFC was defined as a composite of mildly-, moderately-, and severely-reduced T-CFC. Clinical outcomes were assessed by vessel-oriented composite endpoints (VOCE) and major adverse cardiac events (MACE). VOCE and MACE occurred in 19 and 28 patients, respectively. Ischemic T-CFC was found in 88 lesions (28.6%). Kaplan-Meier analysis revealed that lesions with ischemic T-CFC had a significantly higher risk of both VOCE and MACE. Net reclassification index and integrated discrimination improvement index were both significantly improved when ischemic T-CFC was added to the clinical risk model (age, sex, prior stent implantation, and lesion length) for predicting VOCE and MACE. Furthermore, ischemic T-CFC showed significant incremental predictive ability for VOCE and MACE when compared with the clinical risk model + fractional flow reserve ≤ 0.8, or with the clinical model + coronary flow reserve ≤ 2.0. T-CFC categorization improved the risk stratification for both VOCE and MACE and showed incremental prognostic value in patients with deferred revascularization.